{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T23:40:04Z","timestamp":1745797204735,"version":"3.40.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Cytarabine is a prodrug which is activated to cytarabine triphosphate (Ara-CTP) through a series of phosphorylation steps. For considerable leukemic cell death, high level of Ara-CTP is required. Sterile alpha motif and histidine-aspartate domain-containing protein 1<jats:italic> (SAMHD1)<\/jats:italic> and Nucleotide diphosphate kinase-2<jats:italic> (NME2)<\/jats:italic> are genes involved in Ara-CTP metabolism. To best of our knowledge, there are no similar studies focused on the association of different polymorphisms involved Ara-C metabolism on the response to induction chemotherapy among adult AML Egyptian patients. Therefore, the aim of this study was to determine the effect of <jats:italic>SAMHD1<\/jats:italic> rs28372906 and <jats:italic>NME2<\/jats:italic>\u00a0rs3744660 polymorphisms on AML complete remission rate (CR), overall survival (OS), and disease-free survival (DFS) among adult AML Egyptian patients, after Ara-C based induction therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study was a retrospective conducted at the National Cancer Institute, Cairo University, Egypt. The patient group included 136 adult patients with newly diagnosed AML, while the control group included 48 healthy subjects. The clinical history of all studied patients was collected from patient records. Patients and controls were genotyped for <jats:italic>NEM2<\/jats:italic> (rs3744660) and <jats:italic>SAMHD1<\/jats:italic> (rs28372906) by using Taq Man Genotyping assay and Taq Man genotyping master mix (REF: 4,371,353, Applied Biosystems, USA). Real-time PCR assay was performed on Thermo Fisher Quant Studio\u2122 3. The Statistical Package for Social Science version 21.0 was used to analyze our data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Regarding the <jats:italic>SAMHD1<\/jats:italic> (rs28372906) polymorphism, we did not find any genotype variations between patient, and control groups, where all of them were AA genotype. Regarding <jats:italic>NME2<\/jats:italic> (rs3744660) polymorphism the statistical analysis reported significant association between D28 blasts and OS (<jats:italic>P<\/jats:italic>-value\u2009=\u20090.043), while the remaining initial patient characteristics and response to induction were not associated with OS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>CR, DFS, and OS were not significantly associated to <jats:italic>SAMHD1<\/jats:italic> rs28372906 and <jats:italic>NME2<\/jats:italic>\u00a0rs3744660 polymorphisms.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s43046-025-00272-4","type":"journal-article","created":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T23:02:15Z","timestamp":1745794935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of NME2 and SAMHD1 genetic polymorphisms involved in Ara-C metabolism on the response to induction chemotherapy in adult acute myeloid leukemia"],"prefix":"10.1186","volume":"37","author":[{"given":"Lamiaa Ahmed","family":"Fouad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghada Mohamed","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mosaad M.","family":"El-Gammal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman Omar","family":"Rasekh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah Khaled","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman Ali","family":"Ragab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma B.","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"issue":"1","key":"272_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2016.10","volume":"2","author":"A Khwaja","year":"2016","unstructured":"Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, Bloomfield CD, Estey E, Burnett A, Cornelissen JJ. Acute myeloid leukaemia. Nat Rev Dis Primers. 2016;2(1):1\u201322. https:\/\/doi.org\/10.1038\/nrdp.2016.10.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"272_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.beha.2016.10.001","volume":"29","author":"JM Rowe","year":"2016","unstructured":"Rowe JM. AML in 2016: where we are now? Best Pract Res Clin Haematol. 2016;29(4):315\u20139. https:\/\/doi.org\/10.1016\/j.beha.2016.10.001.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"272_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.beha.2013.10.005","volume":"26","author":"F Ravandi","year":"2013","unstructured":"Ravandi F. Relapsed acute myeloid leukemia: why is there no standard of care? Best Pract Res Clin Haematol. 2013;26(3):253\u20139. https:\/\/doi.org\/10.1016\/j.beha.2013.10.005.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"272_CR4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3390\/pharmaceutics14030559","volume":"14","author":"\u00c1 Pinto-Merino","year":"2022","unstructured":"Pinto-Merino \u00c1, Labrador J, Zubiaur P, Alcaraz R, Herrero MJ, Montesinos P, Abad-Santos F, Saiz-Rodr\u00edguez M. Role of pharmacogenetics in the treatment of acute myeloid leukemia: systematic review and future perspectives. Pharmaceutics. 2022;14(3):559. https:\/\/doi.org\/10.3390\/pharmaceutics14030559.","journal-title":"Pharmaceutics"},{"issue":"3","key":"272_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H D\u00f6hner","year":"2010","unstructured":"D\u00f6hner H, Estey EH, Amadori S, Appelbaum FR, B\u00fcchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453\u201374. https:\/\/doi.org\/10.1182\/blood-2009-07-235358.","journal-title":"Blood"},{"issue":"1","key":"272_CR6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0026-895X(25)15031-1","volume":"26","author":"D Kufe","year":"1984","unstructured":"Kufe D, Munroe D, Herrick D, Egan E, Spriggs D. Effects of 1-beta-D-arabinofuranosylcytosine incorporation on eukaryotic DNA template function. Mol Pharmacol. 1984;26(1):128\u201334.","journal-title":"Mol Pharmacol"},{"issue":"8","key":"272_CR7","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.3109\/10428194.2012.676176","volume":"53","author":"E Bach","year":"2012","unstructured":"Bach E, Krahl R, Lange T, Sch\u00fcler F, Al-Ali H, B\u00fcchner T, Haferlach T, D\u00f6lken G, Niederwieser D, Cross M. Delayed processing of bone marrow samples reveals a prognostic pattern of NME mRNA expression in cytogenetically normal acute myeloid leukemia. Leuk Lymphoma. 2012;53(8):1561\u20138. https:\/\/doi.org\/10.3109\/10428194.2012.676176.","journal-title":"Leuk Lymphoma"},{"key":"272_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-018-1463-1","volume":"16","author":"K-W Zhu","year":"2018","unstructured":"Zhu K-W, Chen P, Zhang D-Y, Yan H, Liu H, Cen L-N, Liu Y-L, Cao S, Zhou G, Zeng H. Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML). J Transl Med. 2018;16:1\u201314. https:\/\/doi.org\/10.1186\/s12967-018-1463-1.","journal-title":"J Transl Med"},{"issue":"5","key":"272_CR9","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.3390\/ijms20051230","volume":"20","author":"Y-C Ko","year":"2019","unstructured":"Ko Y-C, Hu C-Y, Liu Z-H, Tien H-F, Ou D-L, Chien H-F, Lin L-I. Cytarabine-resistant FLT3-ITD leukemia cells are associated with TP53 mutation and multiple pathway alterations\u2014possible therapeutic efficacy of cabozantinib. Int J Mol Sci. 2019;20(5):1230. https:\/\/doi.org\/10.3390\/ijms20051230.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"272_CR10","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3109\/10428194.2011.635862","volume":"53","author":"D Braunagel","year":"2012","unstructured":"Braunagel D, Schaich M, Kramer M, Dransfeld C-L, Ehninger G, Mahlknecht U. The T_T genotype within the NME1 promoter single nucleotide polymorphism\u2212 835 C\/T is associated with an increased risk of cytarabine induced neurotoxicity in patients with acute myeloid leukemia. Leuk Lymphoma. 2012;53(5):952\u20137. https:\/\/doi.org\/10.3109\/10428194.2011.635862.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"272_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3390\/cancers10070240","volume":"10","author":"N Tsesmetzis","year":"2018","unstructured":"Tsesmetzis N, Paulin CB, Rudd SG, Herold N. Nucleobase and nucleoside analogues: resistance and re-sensitisation at the level of pharmacokinetics, pharmacodynamics and metabolism. Cancers. 2018;10(7):240. https:\/\/doi.org\/10.3390\/cancers10070240.","journal-title":"Cancers"},{"issue":"14","key":"272_CR12","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.2217\/pgs-2018-0086","volume":"19","author":"AH Elsayed","year":"2018","unstructured":"Elsayed AH, Cao X, Crews KR, Gandhi V, Plunkett W, Rubnitz JE, Ribeiro RC, Pounds SB, Lamba JK. Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. Pharmacogenomics. 2018;19(14):1101\u201310. https:\/\/doi.org\/10.2217\/pgs-2018-0086.","journal-title":"Pharmacogenomics"},{"issue":"20","key":"272_CR13","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544.","journal-title":"Blood"},{"key":"272_CR14","unstructured":"National Comprehensive Cancer Network. NCCN guidelines for patients: acute myeloid leukemia. https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/aml-patient.pdf."},{"issue":"4","key":"272_CR15","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, Dombret H, Ebert BL, Fenaux P, Larson RA. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347. https:\/\/doi.org\/10.1182\/blood-2016-08-733196.","journal-title":"Blood"},{"key":"272_CR16","doi-asserted-by":"crossref","unstructured":"O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby D, Blum W, Coutre SE, De Lima M. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology.\u00a0J Natl Compr Cancer Netw. 2017;15(7):926\u201357.","DOI":"10.6004\/jnccn.2017.0116"},{"key":"272_CR17","doi-asserted-by":"publisher","first-page":"viii371","DOI":"10.1093\/annonc\/mdy286.037","volume":"29","author":"C Ng","year":"2018","unstructured":"Ng C, Ting S, Hwang W, Bajel A, Eek R, McHale M, Shih H, McIntyre N, Kwek J, Lindmark B. A phase IIA dose optimization study of ASLAN003 in acute myeloid leukemia (AML). Ann Oncol. 2018;29:viii371. https:\/\/doi.org\/10.1093\/annonc\/mdy286.037.","journal-title":"Ann Oncol."},{"issue":"S2","key":"272_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1634\/theoncologist.13-S2-19","volume":"13","author":"R Pazdur","year":"2008","unstructured":"Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist. 2008;13(S2):19\u201321. https:\/\/doi.org\/10.1634\/theoncologist.13-S2-19.","journal-title":"Oncologist"},{"issue":"24","key":"272_CR19","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, B\u00fcchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642\u20139. https:\/\/doi.org\/10.1200\/JCO.2003.04.036.","journal-title":"J Clin Oncol"},{"key":"272_CR20","doi-asserted-by":"publisher","unstructured":"Kufe D, Spriggs D, Egan EM, Munroe D. Relationships among Ara-CTP pools, formation of (Ara-C) DNA, and cytotoxicity of human leukemic cells. 1984. https:\/\/doi.org\/10.1182\/blood.V64.1.54.54.","DOI":"10.1182\/blood.V64.1.54.54"},{"issue":"12","key":"272_CR21","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2217\/pgs.13.131","volume":"14","author":"X Cao","year":"2013","unstructured":"Cao X, Mitra AK, Pounds S, Crews KR, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D. RRM1 and RRM2 pharmacogenetics: association wih phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics. 2013;14(12):1449\u201366. https:\/\/doi.org\/10.2217\/pgs.13.131.","journal-title":"Pharmacogenomics"},{"issue":"3","key":"272_CR22","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1124\/jpet.107.128595","volume":"323","author":"JK Lamba","year":"2007","unstructured":"Lamba JK, Crews K, Pounds S, Schuetz EG, Gresham J, Gandhi V, Plunkett W, Rubnitz J, Ribeiro R. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther. 2007;323(3):935\u201345. https:\/\/doi.org\/10.1124\/jpet.107.128595.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"272_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1124\/jpet.111.182873","volume":"339","author":"AK Mitra","year":"2011","unstructured":"Mitra AK, Crews KR, Pounds S, Cao X, Feldberg T, Ghodke Y, Gandhi V, Plunkett W, Dolan ME, Hartford C. Genetic variants in cytosolic 5\u2032-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther. 2011;339(1):9\u201323. https:\/\/doi.org\/10.1124\/jpet.111.182873.","journal-title":"J Pharmacol Exp Ther"},{"key":"272_CR24","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s12185-015-1766-4","volume":"101","author":"J Amaki","year":"2015","unstructured":"Amaki J, Onizuka M, Ohmachi K, Aoyama Y, Hara R, Ichiki A, Kawai H, Sato A, Miyamoto M, Toyosaki M. Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy. Int J Hematol. 2015;101:543\u201353. https:\/\/doi.org\/10.1007\/s12185-015-1766-4.","journal-title":"Int J Hematol"},{"issue":"2","key":"272_CR25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ejca.2012.07.022","volume":"49","author":"K Im Kim","year":"2013","unstructured":"Im Kim K, Huh I-S, Kim I-W, Park T, Ahn K-S, Yoon S-S, Yoon J-H, Oh JM. Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients. Eur J Cancer. 2013;49(2):403\u201310. https:\/\/doi.org\/10.1016\/j.ejca.2012.07.022.","journal-title":"Eur J Cancer"},{"issue":"1","key":"272_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13039-022-00621-1","volume":"15","author":"MG Elnaggar","year":"2022","unstructured":"Elnaggar MG, Mosad E, Makboul A, Shafik EA. Cytogenetic profile of adult acute myeloid leukemia in Egypt: a single-center experience. Mol Cytogenet. 2022;15(1):43. https:\/\/doi.org\/10.1186\/s13039-022-00621-1.","journal-title":"Mol Cytogenet"},{"issue":"1","key":"272_CR27","first-page":"53","volume":"1","author":"H Zawam","year":"2018","unstructured":"Zawam H, Salama R, Alsirafy S, Bishr M. Treatment outcome of acute myeloid leukemia in Egypt: a developing country perspective. Int J Cancer Treat. 2018;1(1):53\u20139.","journal-title":"Int J Cancer Treat"},{"issue":"2","key":"272_CR28","first-page":"106","volume":"19","author":"HM El-Zawahry","year":"2007","unstructured":"El-Zawahry HM, Zeeneldin AA, Samra MA, Mattar MM, El-Gammal MM, Abd El-Samee A, Darwish T. Cost and outcome of treatment of adults with acute myeloid leukemia at the National Cancer Institute-Egypt. J Egypt Natl Canc Inst. 2007;19(2):106\u201313.","journal-title":"J Egypt Natl Canc Inst"},{"issue":"9","key":"272_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.21608\/EJHBMT.2021.193653","volume":"8","author":"MO Azzazi","year":"2021","unstructured":"Azzazi MO, Kourashy E, Abd El Wahab S, Nabih NA, Abdou Hussein AN. Evaluation of ADAM28 expression in adult Egyptian acute myeloid leukemia patients and its impact on outcome. Egypt J Hematol Bone Marrow Transpl. 2021;8(9):37\u201348. https:\/\/doi.org\/10.21608\/EJHBMT.2021.193653.","journal-title":"Egypt J Hematol Bone Marrow Transpl."},{"issue":"2","key":"272_CR30","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nm.4255","volume":"23","author":"C Schneider","year":"2017","unstructured":"Schneider C, Oellerich T, Baldauf H-M, Schwarz S-M, Thomas D, Flick R, Bohnenberger H, Kaderali L, Stegmann L, Cremer A. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nat Med. 2017;23(2):250\u20135. https:\/\/doi.org\/10.1038\/nm.4255.","journal-title":"Nat Med"},{"issue":"2","key":"272_CR31","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nm.4265","volume":"23","author":"N Herold","year":"2017","unstructured":"Herold N, Rudd SG, Ljungblad L, Sanjiv K, Myrberg IH, Paulin CB, Heshmati Y, Hagenkort A, Kutzner J, Page BD. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies. Nat Med. 2017;23(2):256\u201363. https:\/\/doi.org\/10.1038\/nm.4265.","journal-title":"Nat Med"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00272-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-025-00272-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00272-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T23:02:17Z","timestamp":1745794937000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-025-00272-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["272"],"URL":"https:\/\/doi.org\/10.1186\/s43046-025-00272-4","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"30 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the National Cancer Institute\u2019s Ethical Committee, Cairo University, Egypt (approved date 09 February 2020; approval number 201920027.3), in accordance with the World Medical Association\u2019s Code of Ethics (Declaration of Helsinki), as published in the British Medical Journal (18 July 1964).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}